Shanghai Serum Bio-Technology (688163)

Search documents
下周解禁股名单出炉
Zheng Quan Shi Bao Wang· 2025-09-06 06:27
Summary of Key Points Core Viewpoint - The A-share market will see a significant unlock of restricted shares next week, with a total market value exceeding 96 billion yuan, which may impact stock prices of the affected companies [2]. Group 1: Unlock Scale and Impact - A total of 40 stocks will have their restricted shares unlocked from September 8 to 12, with a combined market value of 966.01 billion yuan [2]. - Among these, 12 stocks have an unlock market value exceeding 1 billion yuan, with notable companies like Times Electric, Southern Power Storage, and BGI Genomics having unlock values of 278.23 billion yuan, 230.81 billion yuan, and 133.82 billion yuan respectively [2][4]. Group 2: Unlock Proportions - Thirteen stocks have an unlock ratio exceeding 10%, indicating a potentially significant impact on their stock prices. Companies such as Minshida, Southern Power Storage, and Sailun Bio have unlock ratios above 50% [5]. - The highest unlock ratio is seen in Minshida at 66.23%, followed by Southern Power Storage at 65.30% and Sailun Bio at 59.00% [7]. Group 3: Company Performance - Times Electric's major shareholder, CRRC Zhuzhou Electric Locomotive Research Institute, will unlock approximately 590 million shares, accounting for 43.42% of its total share capital. The company reported a revenue of 12.214 billion yuan for the first half of 2025, a year-on-year increase of 17.95%, and a net profit of 1.672 billion yuan, up 12.93% [4]. - Minshida, listed on the Beijing Stock Exchange, achieved a revenue of 237 million yuan in the first half of 2025, reflecting a year-on-year growth of 27.91%, with a net profit of 63.03 million yuan, up 42.28% [8]. Group 4: Institutional Investment Returns - Institutions that participated in the private placements of stocks like Western Gold and Southern Power Storage are expected to see positive returns from the unlock, with Western Gold's return exceeding 180% and Southern Power Storage's over 70% [8].
上海赛伦生物技术股份有限公司 关于完成工商变更登记并换发营业执照的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-09-05 04:56
Core Viewpoint - Shanghai Sairun Biotechnology Co., Ltd. has completed the registration of business changes and obtained a new business license, reflecting significant corporate governance updates and operational scope adjustments [1][2]. Group 1: Corporate Changes - The company held board and supervisory meetings on July 24, 2025, to approve the cancellation of the supervisory board and changes to the business scope and articles of association [1]. - The company convened a temporary shareholders' meeting on August 11, 2025, to ratify the aforementioned changes [1]. - The updated business registration information includes a registered capital of RMB 108.22 million and a new operational scope that encompasses drug production, import/export, and various medical device services [2]. Group 2: Investor Communication - The company plans to participate in a collective performance briefing for the biotech and CXO industry from September 15, 2025, to discuss its semi-annual results and address investor inquiries [4][5]. - Investors can submit questions from September 8 to September 12, 2025, for discussion during the briefing [7]. - The briefing will be held online at the Shanghai Stock Exchange Roadshow Center, allowing for interactive communication with investors [6][8].
赛伦生物:关于参加2025年半年度科创板生物制品及CXO行业集体业绩说明会的公告
Zheng Quan Ri Bao· 2025-09-04 13:36
Group 1 - The company, Sairen Bio, announced its plan to participate in the 2025 semi-annual performance briefing for the biopharmaceutical and CXO industry on September 15, 2025 [2]
赛伦生物:关于完成工商变更登记并换发营业执照的公告
Zheng Quan Ri Bao· 2025-09-04 12:23
Group 1 - The company, Sairun Bio, announced the convening of its fourth board meeting and the sixth supervisory meeting on July 24, 2025, to review and approve the proposal to cancel the supervisory board, change the business scope, and amend the business registration [2] - The company held its first extraordinary shareholders' meeting on August 11, 2025, where the aforementioned matters were approved [2] - The company has completed the business registration and filing procedures for the above matters and has obtained a new business license from the Shanghai Municipal Market Supervision Administration [2]
赛伦生物: 赛伦生物:关于参加2025年半年度科创板生物制品及CXO行业集体业绩说明会的公告
Zheng Quan Zhi Xing· 2025-09-04 09:11
Group 1 - The company will hold a performance briefing on September 15, 2025, from 15:00 to 17:00 [2][3] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an online interactive format [2][3] - Key company personnel, including the chairman and financial director, will participate in the briefing [2][3] Group 2 - Investors can submit questions for the briefing from September 8 to September 12, 2025, before 16:00 [3] - The company will address commonly asked questions during the briefing [2][3] - After the briefing, investors can access the main content and outcomes through the Shanghai Stock Exchange Roadshow Center [3]
赛伦生物: 赛伦生物:关于完成工商变更登记并换发营业执照的公告
Zheng Quan Zhi Xing· 2025-09-04 09:11
Core Points - The company has completed the registration of changes in business operations and has obtained a new business license [2] - The company held board and shareholder meetings to approve the cancellation of the supervisory board and amendments to the articles of association [1][2] - The updated business scope includes drug production, import and export, and various medical device operations [2] Group 1 - The company held its fourth board meeting on July 24, 2025, and the first extraordinary general meeting on August 11, 2025, to approve significant changes [1] - The new registered capital of the company is RMB 108.22 million [2] - The company is now registered as a joint-stock company with a unified social credit code of 91310000631521822M [2] Group 2 - The company's business scope now includes the production and sale of various classes of medical devices and drug-related services [2] - The company is authorized to engage in technology services, development, consulting, and investment management [2] - The registered address of the company is located at 1288 Huqing Road, Qingpu District, Shanghai [2]
赛伦生物(688163) - 赛伦生物:关于参加2025年半年度科创板生物制品及CXO行业集体业绩说明会的公告
2025-09-04 09:00
证券代码:688163 证券简称:赛伦生物 公告编号:2025-025 上海赛伦生物技术股份有限公司 关于参加 2025 年半年度科创板生物制品及 CXO 行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 会 议 召 开 地 点 : 上 海 证 券 交 易 所 上 证 路 演 中 心 ( 网 址 : https://roadshow.sseinfo.com/) 会议召开方式:上证路演中心网络文字互动 2025 年 9 月 8 日(星期一)至 9 月 12 日(星期五)16:00 前登录上证路 演中心网站首页点击"提问预征集"栏目或通过公司邮箱 dmb@serum-china.com 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 上海赛伦生物技术股份有限公司(以下简称"公司")已于 2025 年 8 月 26 日发布公司 2025 年半年度报告,为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况,公司计划于 2025 年 9 月 15 日 (星期 ...
赛伦生物(688163) - 赛伦生物:关于完成工商变更登记并换发营业执照的公告
2025-09-04 09:00
证券代码:688163 证券简称:赛伦生物 公告编号:2025-026 上海赛伦生物技术股份有限公司 关于完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 上海赛伦生物技术股份有限公司(以下简称"公司")于 2025 年 7 月 24 日召开第四届董事会第七次会议及第四届监事会第六次会议,审议通过了《关于 取消监事会、变更经营范围、修订<公司章程>并办理工商变更登记的议案》, 并于 2025 年 8 月 11 日召开 2025 年第一次临时股东大会,审议通过了上述事项。 具体内容详见公司 2025 年 7 月 25 日、2025 年 8 月 12 日于上海证券交易所网站 (www.sse.com.cn)披露的《关于取消监事会、变更经营范围、修订<公司章程> 及修订和制定公司部分治理制度的公告》(公告编号:2025-016)、《2025 年第 一次临时股东大会决议公告》(公告编号:2025-019)。 近日,公司已完成上述事项的工商变更登记及备案手续,并取得了上海市市 场监督管理局换发的《 ...
赛伦生物(688163) - 赛伦生物:首次公开发行限售股上市流通公告
2025-09-03 09:31
证券代码:688163 证券简称:赛伦生物 公告编号:2025-024 上海赛伦生物技术股份有限公司 首次公开发行限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏,并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示: 本次股票上市类型为首发限售股份;股票认购方式为网下,上市股数为 63,848,000股。 本次股票上市流通总数为63,848,000股。 本次股票上市流通日期为2025 年 9 月 11 日。 一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 1 月 25 日出具的《关于同意上海赛 伦生物技术股份有限公司首次公开发行股票注册的批复》(证监许可【2022】204 号),同意上海赛伦生物技术股份有限公司(以下简称"公司"或"赛伦生物") 首次公开发行股票的注册申请。公司首次向社会公众公开发行人民币普通股(A 股)股票 27,060,000 股,并于 2022 年 3 月 11 日在上海证券交易所科创板上市, 发行完成后股本总数为 108,220,000 股,其中有限售条件流通股 83,456,396 股,占 ...
赛伦生物(688163) - 方正证券承销保荐有限责任公司关于上海赛伦生物技术股份有限公司首次公开发行限售股上市流通的核查意见
2025-09-03 09:31
一、本次上市流通的限售股类型 根据中国证券监督管理委员会于 2022 年 1 月 25 日出具的《关于同意上海赛 伦生物技术股份有限公司首次公开发行股票注册的批复》(证监许可[2022]204 号),同意公司首次公开发行股票的注册申请。公司首次向社会公众公开发行人 民币普通股(A 股)股票 27,060,000 股,并于 2022 年 3 月 11 日在上海证券交易 所科创板上市,发行完成后股本总数为 108,220,000 股,其中有限售条件流通股 83,456,396 股,占公司股本总数的 77.12%,无限售条件流通股 24,763,604 股,占 公司股本总数的 22.88%。 方正证券承销保荐有限责任公司 关于上海赛伦生物技术股份有限公司 首次公开发行限售股上市流通的核查意见 方正证券承销保荐有限责任公司(以下简称"保荐机构")作为上海赛伦生 物技术股份有限公司(以下简称"公司"或"赛伦生物")首次公开发行股票并 在科创板上市的保荐机构及持续督导机构,根据《证券发行上市保荐业务管理办 法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司 自律监管指引第 1 号—规范运作》等法律法规 ...